Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.62 |
| ▸ | RARB | P10826 | 8/20 | 0.62 |
| ▸ | RARG | P13631 | 8/20 | 0.62 |
| ▸ | RXRG | P48443 | 11/20 | 0.54 |
| ▸ | RXRB | P28702 | 9/20 | 0.54 |
| ▸ | RARA | P10276 | 4/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882513 | 1.00 | RXRA (0.62) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL7565108 | 0.85 | KDM4E (0.47) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL7567586 | 0.85 | KDM4E (0.47) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8362236 | 0.84 | RXRA (0.60) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8362245 | 0.84 | RXRA (0.60) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8189844 | 0.84 | RXRA (0.62) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8189841 | 0.84 | RXRA (0.62) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL9049113 | 0.83 | RARB (0.50) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL8487114 | 0.83 | RARB (0.50) | RXRARARBRARGRXRGRXRB | |
| SCHEMBL9049102 | 0.83 | RARB (0.50) | RXRARARBRARGRXRGRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | BOLLAG WERNER | 2008-10-16 | — | — | US | claimed |
| EP-0997455-A1 | Restricted 9-cis retenoids | American Cyanamid Company (US) | 2000-05-03 | — | — | EP | claimed |
| EP-0775103-B1 | RETINOIC ACID X-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 1999-06-09 | — | — | EP | claimed |
| US-5801253-A | Retinoic acid X-receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 1998-09-01 | — | — | US | claimed |
| EP-0775103-A1 | RETINOIC ACID X-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-05-28 | — | — | EP | claimed |
| EP-0718285-A2 | Restricted 9-cis-retinoids | American Cyanamid Company (US) | 1996-06-26 | — | — | EP | claimed |
| WO-1996005165-A1 | RETINOIC ACID X-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-02-22 | — | — | WO | claimed |
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | BOLLAG WERNER | 2008-10-16 | — | — | US | disclosed |
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | BOLLAG WERNER | 2008-10-16 | — | — | US | disclosed |
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | BOLLAG WERNER | 2008-10-16 | — | — | US | disclosed |
| EP-0848696-B1 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2002-08-28 | — | — | EP | disclosed |
| US-20020082419-A1 | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN SALES, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6313163-B1 | ADMINISTERING 2,4-PENTADIENOIC ACID DERIVATIVE FOR THERAPY OF DISEASE OR CONDITION RESPONSIVE TO THERAPY BY RETINOIDS | ALLERGEN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| US-5801253-A | Retinoic acid X-receptor ligands | HOFFMANN-LA ROCHE INC. (US) | 1998-09-01 | — | — | US | disclosed |
| US-5780647-A | 2,4-Pentadienoic acid derivatives having retinoid-like biological activity | ALLERGAN (US) | 1998-07-14 | — | — | US | disclosed |
| US-5675033-A | FOR TREATMENT OF SKIN DISORDERS | ALLERGAN (US) | 1997-10-07 | — | — | US | disclosed |
| US-5663367-A | REGULATOR OF CELL PROLIFERATION AND DIFFERENTIATION; TREATMENT OF SKIN DISORDERS, ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0775103-A1 | RETINOIC ACID X-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-05-28 | — | — | EP | disclosed |
| EP-0718285-A2 | Restricted 9-cis-retinoids | American Cyanamid Company (US) | 1996-06-26 | — | — | EP | disclosed |
| WO-1996005165-A1 | RETINOIC ACID X-RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082419-A1 | 2,4-pentadienoic acid derivatives having retinoid-like biological activity | RXRA, RXRB, CBR1 | RXRA 1/4885RARB 13/4885RARG 30/4885 |
| US-20080255206-A1 | Rxr Agonists and Antagonists, Alone or in Combination with Ppar Ligands, in the Treatment of Metabolic and Cardiovascular Diseases | RXRA, RXRG, RXRB | RXRA 1/4885RARB 10/4885RARG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.